1. Scrip
  2. >>Therapy Areas

Shkreli Subpoenaed On Drug Prices, Refuses To Give Up Records

 
• By Donna Young

Martin Shkreli, the former hedge-fund manager who recently lost his job as CEO at two drug companies after being arrested on fraud charges, has been subpoenaed by the House Oversight and Government Reform Committee to testify at a Jan. 26 hearing focused on the increases in the prices of older medicines – like the 5,000% spike in the cost for the toxoplasmosis drug Daraprim (pyrimethamine), which is sold by Turing Pharmaceuticals Inc., one of the firms he started and then was booted from.

Martin Shkreli, the former hedge-fund manager who recently lost his job as CEO at two drug companies after being arrested on fraud charges, has been subpoenaed by the House Oversight and Government Reform Committee to testify at a Jan. 26 hearing focused on the increases in the prices of older medicines – like the 5,000% spike in the cost for the toxoplasmosis drug Daraprim (pyrimethamine), which is sold by Turing Pharmaceuticals Inc., one of the firms he started and then was booted from.

"I have been trying for the better part of a year to get information from Martin Shkreli about his outrageous...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Anti-infective

More from Therapy Areas

Novartis Secures Approval For First Malaria Therapy for Babies

 
• By Kevin Grogan

Coartem Baby to be rolled out in eight African countries in the autumn.

Could Apogee Rival Regeneron/Sanofi, Lilly After Phase II Eczema Data Win?

 
• By Manas Mishra

Apogee Therapeutics reports data from Phase II APEX trial of its long-acting antibody against atopic dermatitis, showing similar efficacy to Regeneron/Sanofi’s Dupixent and Eli Lilly’s Ebglyss.

Cogent Peaks With Bezaclastinib SUMMIT Results

 
• By Alaric DeArment

The biotech announced positive topline results from the Phase II SUMMIT study in non-advanced systemic mastocytosis, with data for advanced SM and GIST expected later this year.